NEW YORK, Dec. 19-Lynx Therapeutics said today that it has a service agreement with the Woods Hole Oceanographic Institution to study gene expression in a marine dinoflagellate that causes red tides.
Lynx will receive payments from the institute to use its Massively Parallel Signature Sequencing technology on samples of Alexandrium fundyense, an algae that can cause paralytic shellfish poisoning in people who eat contaminated shellfish.
The company's platform will be used to study the physiology of algal bloom formation and the production of neurotoxins, with the aim of creating new ways to monitor shellfish.
Financial details of the agreement were not revealed. Yesterday, Lynx also announced that it has received a delisting noticefrom Nasdaq; the company plans to appeal the notice.